These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 5509487)

  • 1. [Biochemistry and treatment of Parkinson's disease].
    Barbeau A
    Laval Med; 1970 Sep; 41(7):902-5. PubMed ID: 5509487
    [No Abstract]   [Full Text] [Related]  

  • 2. Dopaminergic nervous transmission in Parkinson's disease.
    Rinne UK; Sonninen V; Riekkinen P; Laaksonen H
    Med Biol; 1974 Jun; 52(3):208-17. PubMed ID: 4371255
    [No Abstract]   [Full Text] [Related]  

  • 3. Metabolism of L-dihydroxyphenylalanine by patients with Parkinson's disease.
    Tyce GM; Muenter MD; Owen CA
    Mayo Clin Proc; 1970 Sep; 45(9):645-56. PubMed ID: 5311767
    [No Abstract]   [Full Text] [Related]  

  • 4. Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease.
    Streifler M; Vardi Y; Kesten M; Oberman Z; Herzberg M
    Isr J Med Sci; 1972 May; 81(5):597-601. PubMed ID: 5042950
    [No Abstract]   [Full Text] [Related]  

  • 5. [Biochemical and clinical correlations in Parkinson's disease].
    Barbeau A
    Rev Neurol (Paris); 1972 Aug; 127(2):253-64. PubMed ID: 4603361
    [No Abstract]   [Full Text] [Related]  

  • 6. The biochemistry of catecholamines in relation to Parkinson's disease.
    Hinterberger H
    Aust N Z J Med; 1971 May; 1():Suppl 1:14-8. PubMed ID: 5292808
    [No Abstract]   [Full Text] [Related]  

  • 7. Homovanillic acid in the ventricular fluid of patients with Parkinson's disease and other extrapyramidal diseases.
    Papeschi R; Molina-Negro P; Sourkes TL; Hardy J; Bertrand C
    Laval Med; 1970 Sep; 41(7):899-901. PubMed ID: 5509486
    [No Abstract]   [Full Text] [Related]  

  • 8. The probenecid test in Parkinson's disease.
    Lakke JP; Korf J; Hoorntje S; Schut T; van Praag HM
    Psychiatr Neurol Neurochir; 1973; 76(2):139-46. PubMed ID: 4700931
    [No Abstract]   [Full Text] [Related]  

  • 9. EEG and urinary non-catecholic amine changes during L-dopa therapy of Parkinson's disease.
    Marjerrison G; Boulton AA; Rajput AH
    Dis Nerv Syst; 1972 Mar; 33(3):164-9. PubMed ID: 5022451
    [No Abstract]   [Full Text] [Related]  

  • 10. [Study of 3-4-dihydroxyphenylacetic acid, a dopamine catabolite, in patients with Parkinson's disease before treatment with L-dopa].
    Samson M; Bohuon C; Augustin P; Comoy E; Pouliquen A
    Rev Neurol (Paris); 1972 Aug; 127(2):315-7. PubMed ID: 4666641
    [No Abstract]   [Full Text] [Related]  

  • 11. [The therapeutic use of L-DOPA in Parkinson's disease. Biochemical, pharmacological and clinical considerations].
    Morselli PL; Rizzo M; Tognoni G
    Recenti Prog Med; 1970 Feb; 48(2):97-124. PubMed ID: 5467589
    [No Abstract]   [Full Text] [Related]  

  • 12. Toxic delirium after L-dopa medication.
    Birkmayer W
    J Neural Transm Suppl; 1978; (14):163-6. PubMed ID: 290736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa.
    Gumpert J; Sharpe D; Curzon G
    J Neurol Sci; 1973 May; 19(1):1-12. PubMed ID: 4715017
    [No Abstract]   [Full Text] [Related]  

  • 14. [Study of dopamine and noradrenaline in the brains of three patients with Parkinson's disease who died in the course of treatment with L-dopa].
    Buscaino GA; Sori A; Campanella G
    Rev Neurol (Paris); 1972 Aug; 127(2):301-2. PubMed ID: 4666634
    [No Abstract]   [Full Text] [Related]  

  • 15. The balance of biogenic amines as condition for normal behaviour.
    Birkmayer W; Danielczyk W; Neumayer E; Riederer P
    J Neural Transm; 1972; 33(2):163-78. PubMed ID: 4643007
    [No Abstract]   [Full Text] [Related]  

  • 16. [Drug-induced Parkinson's syndrome].
    Degkwitz R
    Dtsch Med Wochenschr; 1972 Jun; 97(22):882. PubMed ID: 5032182
    [No Abstract]   [Full Text] [Related]  

  • 17. The metabolism of orally administered L-dopa in Parkinson patients.
    Cote LJ; Cohen G; Yahr MD
    Trans Am Neurol Assoc; 1971; 96():222-3. PubMed ID: 5159086
    [No Abstract]   [Full Text] [Related]  

  • 18. Central monoamine metabolism in Parkinson's disease.
    Chase TN; Ng LK
    Arch Neurol; 1972 Dec; 27(6):486-91. PubMed ID: 5083866
    [No Abstract]   [Full Text] [Related]  

  • 19. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH; Bowers MB
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pathomechanism and pharmacological treatment of Parkinson's disease].
    Pakszys W
    Pol Tyg Lek; 1971 Jun; 26(25):965-7. PubMed ID: 4935461
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.